1. Introduction {#sec1}
===============

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by autoantibody production, immune complex deposition, and various clinical systemic manifestations that affect various organs. The pathogenesis of SLE involves complex interactions between genetic and environmental factors and the adaptive and innate immune systems. The breakdown of immunologic self-tolerance, that is, the control of self- and non-self-discrimination, results in the development of autoimmune diseases. Therefore, elucidating the mechanisms that regulate self-tolerance is important for protecting against self-directed immune responses and autoimmune diseases. On the other hand, proinflammatory cytokines are involved in the generalized immune dysregulation of SLE, as well as the local inflammatory response, which leads to tissue injury. The regulation of the proinflammatory activity of these cytokines is perceived to be mediated by anti-inflammatory and immunosuppressive cytokines such as interleukin- (IL-) 10, transforming growth factor- (TGF-) *β*, IL-27, or IL-35.

Treatment for SLE, as well as other autoimmune diseases, relies on the use of corticosteroids and immunosuppressive drugs, which are nonspecific and can cause adverse effects. Improved diagnosis and management of the disease have contributed to an improvement in its prognosis. However, patients with SLE still display increased mortality compared with the general population. Thus, there is a need for novel therapies that are specific and display improved efficacy and lower toxicity than the current therapies for SLE. Knowledge about Tregs and regulatory cytokines would not only provide new insights into the pathogenesis of SLE but could be also used to develop various clinical applications.

2. Role of Tregs in Autoimmune Diseases {#sec2}
=======================================

The regulation of lymphocyte survival is required for the maintenance of lymphoid homeostasis, which prevents the development of autoimmune diseases. The existence of autoreactive T cells in healthy individuals suggests that peripheral tolerance mechanisms exist to control the responses of these cells. Accumulating evidence has indicated that clonal deletion and anergy, as well as T-cell-mediated control of self-reactive T cells contribute to the maintenance of self-tolerance. Tregs are now recognized as the mediators of peripheral tolerance and potent suppressors of excessive immune responses. Several Treg subtypes with distinct phenotypes, cytokine production profiles, and modes of action have been described. In the CD4^+^ regulatory T-cell compartment, CD4^+^CD25^+^ T cells (CD4^+^CD25^+^ Treg) and IL-10-producing type 1 T-regulatory cells (Tr1) have been described \[[@B1], [@B2]\]. Knowledge about the various developmental pathways and mechanisms of action of Treg-associated cytokines is required to develop novel specific therapies for SLE.

3. Role of CD4^+^CD25^+^ Treg in SLE {#sec3}
====================================

Extensive studies in mice and humans have indicated that CD4^+^CD25^+^ Treg belong to an important subset of Tregs. CD4^+^CD25^+^ Treg, which is naturally occurring and expresses forkhead-winged helix protein-3 (Foxp3), is a potent inhibitor of various immune responses \[[@B3]\]. Depletion or functional defect of CD4^+^CD25^+^ Treg leads to the development of autoimmune diseases in normal animals. CD4^+^CD25^+^ Treg are produced by the thymus as a distinct and mature subpopulation of T cells. Genetic alterations that affect the development or function of CD4^+^CD25^+^ Treg result in the development of autoimmune disease like IPEX syndrome and other inflammatory disorders in humans. In addition, decreased numbers of CD4^+^CD25^+^ Treg were found in some studies of SLE patients, especially during active disease. On the other hand, several investigators have reported that defective CD4^+^CD25^+^ Treg activity is correlated with the downregulated expression of Foxp3 \[[@B4]--[@B6]\]. Miyara et al. reported that CD4^+^CD25^+^ Treg isolated from SLE patients exhibited the same phenotypic and functional characteristics as corresponding cells in healthy controls \[[@B7]\]. However, lupus CD4^+^CD25^+^ Treg do not accumulate in either the lymph nodes or the inflamed kidneys and are more susceptible to Fas-induced apoptosis than those of healthy control. The accumulated data suggest that strategies for enhancing the function of CD4^+^CD25^+^ Treg might be beneficial for patients with SLE. The differences between the results of the various studies of CD4^+^CD25^+^ Treg in SLE patients might have been due to differences in the stage and activity of disease, disease manifestations, and the confounding influence of medical therapies. In addition, the use of different surface markers for defining CD4^+^CD25^+^ Treg might also have affected the results of these studies. Recently, Miyara et al. identified three subpopulations among human Foxp3 expressing cells, CD45RA^+^Foxp3^low^ resting Treg, CD45RA^−^Foxp3^high^ activated Treg, and CD45RA^−^Foxp3^low^ cytokine-secreting cells. They reported that CD45RA^−^Foxp3^low^ non-Treg fraction increased to form a distinct population in active SLE \[[@B8]\].

Lupus-prone mouse models, which are more homogeneous than SLE patients and can be left untreated, might give us more precise information about  CD4^+^CD25^+^ Treg. (NZB × NZW) F~1~ (BWF~1~) and (SWR × NZB) F~1~ (SNF~1~) mice, which spontaneously develop lupus-like disease, had a lower percentage of CD4^+^CD25^+^ Treg than non-SLE-prone mice \[[@B9]\]. Reduced numbers of CD4^+^CD25^+^ Treg were also detected in mice that were congenic for the NZM2410 *sle1* locus  \[[@B10]\], and the reduced number of CD4^+^CD25^+^ Treg was associated with downregulated Foxp3 expression. Other lupus-prone MRL/lpr mice exhibited a normal percentage of CD4^+^CD25^+^ Treg, and their Foxp3 mRNA and protein expression levels were not altered. However, MRL/lpr CD4^+^CD25^+^ Treg exhibited a reduced capacity to suppress the proliferation and secretion of proinflammatory cytokines in effector cells \[[@B11]\]. In BWF~1~ mice, the number and frequency of CD4^+^CD25^+^ Treg were increased, and *in vitro* suppressive activity in lymphoid organs was intact \[[@B12]\]. However, the adoptive transfer of exogenously expanded CD4^+^CD25^+^ Treg to BWF~1~ mice reduced renal pathology and improved survival in BWF~1~ mice, supporting the protective role of these cells in lupus pathogenesis \[[@B13]\], and the induction of mucosal tolerance via the administration of the histone peptide H471 restored the lower numbers of CD4^+^CD25^+^ Treg in BWF~1~ mice to the levels of normal mice \[[@B9]\]. Kang et al. showed that administration of low doses of the nucleosomal histone peptide H4~71--94~ for tolerance induction in SNF~1~ mice ameliorates the manifestations of the disease, prolongs survival, and increases the number of CD4^+^CD25^+^ Treg. Low-dose H4~71--94~ therapy suppressed interferon- (IFN-) *γ* production by pathogenic T cells, autoantibody production, and lupus-associated responses upon their adoptive transfer *in vivo* \[[@B14]\]. High intravenous doses of a synthetic peptide (pConsensus \[pCons\]) based on a shared CDR1/framework 2 epitope encoded within the variable heavy chain regions of several murine anti-dsDNA immunoglobulins also exhibited therapeutic activity in BWF~1~ mice to prolong survival \[[@B15]\]. The administration of the tolerogenic peptide led to the expansion of peptide-reactive CD4^+^CD25^+^ Treg that inhibited the production of anti-dsDNA antibody-producing cells *in vitro* \[[@B16], [@B17]\].

Thus, Treg cell therapy could be a rational approach for the treatment of lupus, and investigators are currently attempting to expand its use to include the treatment of other autoimmune diseases. The specific activities of CD4^+^CD25^+^ Treg have been demonstrated in different animal models of autoimmune diseases (e.g., autoimmune diabetes, autoimmune thyroiditis, and experimental autoimmune encephalomyelitis (EAE)). For instance, CD4^+^CD25^+^ Treg expressing the T-cell receptor (TCR) specific to an islet antigen were reported to efficiently suppress and even reverse early onset of diabetes in nonobese diabetic (NOD) mice, whereas polyclonal CD4^+^CD25^+^ Treg were considerably less effective \[[@B18], [@B19]\]. This suggests that regulatory T-cell function depends on the antigen specificity. Therefore, expanding antigen-specific CD4^+^CD25^+^ Treg may be a promising approach in treating autoimmune diseases including SLE \[[@B20]\].

4. Role of IL-10 in SLE {#sec4}
=======================

IL-10 impedes the activation/expansion of autoreactive lymphocytes via various mechanisms. It is produced mainly by monocytes/macrophages and T-cell subsets including Tr1, CD4^+^CD25^+^ Treg, and T-helper (Th) 1 cells. IL-10 regulates immune cell function through a transmembrane receptor complex, composed of IL-10 receptor *α* (R*α*) and IL-10R*β*. In monocytes/macrophages, IL-10 diminishes the production of inflammatory mediators, inhibits antigen presentation, and prevents specific and nonspecific immune reactions that cause tissue damage. At the same time, monocytes/macrophages increase antigen uptake and function as scavengers. IL-10 prevents the activation of antigen-presenting cells (APC) and downregulates the expression of costimulatory molecules. Recent studies have also revealed that IL-10 regulates autoreactive T cells in NOD mice \[[@B21], [@B22]\]. T cells that were generated *in vitro* and produced high levels of IL-10 inhibited the development of EAE \[[@B23]\]. The generation of antigen-specific T cells that produce IL-10 at sites of inflammation would be a promising strategy to the treatment of autoimmunity. Furthermore, IL-10 appears to play a role in Treg commitment and function \[[@B24]\] and so might be beneficial in SLE.

On the other hand, IL-10 boosts B-cell proliferation and immunoglobulin class switching, resulting in enhanced antibody production and increased inflammation. Several stimuli, including anti-dsDNA antibodies and immune complexes containing Fc**γ**RII, trigger IL-10 production \[[@B25], [@B26]\]. IL-10 has also immunostimulatory effects on CD8^+^ T cells and NK cells, especially in combination with other cytokines, such as IL-18 \[[@B27], [@B28]\]. In patients with SLE, an elevated IFN-**γ**/IL-10 ratio was observed in active class IV lupus nephritis and vice versa in class V nephritis \[[@B29]\]. IL-10 is overproduced by the B cells and monocytes of SLE patients \[[@B30]--[@B32]\], displays increased serum levels in SLE patients \[[@B32], [@B33]\], and is associated with disease activity \[[@B34]\]. Interestingly, continuous therapy from young age with IL-10 antibodies ameliorated autoimmunity in BWF~1~ mice \[[@B35]\]. In accordance with the therapeutic effect of anti-IL-10 antibodies, the continuous administration of recombinant IL-10 increased disease activity \[[@B35]\]. Interestingly, coadministration of blocking anti-tumor necrosis factor (TNF) antibodies cancelled the protective effect of anti-IL-10 antibodies \[[@B35]\], suggesting some unknown immunoregulatory balance between these two cytokines in BWF~1~ mice. Moreover, IL-10 blockade limited the renal damage in animal models of lupus nephritis \[[@B36]\]. The observed downregulation of T-cell activation in peripheral blood mononuclear cells from SLE patients was consistent with these effects \[[@B37]\]. In a small, uncontrolled, open-label study involving patients with mild disease, anti-IL-10 monoclonal antibody improved cutaneous lesions, joint symptoms, and the SLE disease activity index \[[@B38]\]. B-cell secretion of IL-10 might regulate dendritic cell (DC) and T-cell function, promoting Th2 deviation of the immune response \[[@B39]\]. In turn, IL-10 might contribute to a number of the earlier peripheral B-cell abnormalities observed in SLE, including plasma cell expansion \[[@B40]\]. These findings suggest that anti-IL-10 therapy with an agent that is suitable for use in humans might benefit some patients with SLE. However, increased numbers of IL-10-producing cells were also reported in first-degree relatives as well as healthy spouses \[[@B41], [@B42]\]. The contribution of IL-10 genotypes and IL-10 promoter polymorphisms to IL-10 overproduction has not been confirmed yet \[[@B42], [@B43]\]. In addition to environmental factors, both genetic and disease-induced events are required for the pathogenesis of lupus. Some of the proinflammatory effects of IL-10 might be displayed in the presence of other cytokines, such as IL-18 \[[@B28], [@B44]\], and the cytokines produced endogenously at inflammatory sites during various disease stages might modify the effect of IL-10. The modified development and characterization of IL-10 should be investigated further to aid the development of novel immunosuppressive therapies.

We recently reported on IL-10-secreting CD4^+^CD25^−^Foxp3^−^ Treg that characteristically express both the lymphocyte activation gene-3 (LAG-3) and early growth response gene-2 (Egr-2), and the ectopic expression of Egr-2 conferred suppressive functions on naïve CD4^+^ cells \[[@B45]\]. The adoptive transfer of CD4^+^CD25^−^LAG3^+^ Treg from MRL/+ mice suppressed the progression of nephritis and autoantibody production in MRL/lpr mice (unpublished observation). In consistency with previous report \[[@B11]\], CD4^+^CD25^+^ Treg from MRL/+ mice revealed no significant therapeutic effect upon being transferred to MRL/lpr mice. These results indicate that IL-10-producing CD4^+^CD25^−^LAG3^+^ Treg play a critical role in preventing the development of autoimmune diseases characterized with autoantibody production.

Interestingly, Huber et al. reported that both Foxp3^−^ and Foxp3^+^ regulatory CD4^+^ T cells control Th17 cells in an IL-10-dependent manner \[[@B46]\]. Th17 is a distinct helper T-cell subset that produces IL-17. Accumulated data suggest that IL-17 contributes to the pathogenesis of SLE. In lupus-prone BXD2 mice, IL-17 increases the number of IL-17-producing T cells, which help B cells, and accelerates germinal center formation in the spleen \[[@B47]\]. The frequency of IL-17-producing T cells also showed an increase in the peripheral blood of SLE patients. Patients with SLE display higher plasma levels of IL-17 and IL-23 than healthy controls, and their plasma IL-17 levels exhibit a positive correlation with disease activity \[[@B48]\]. CD3^+^CD4^−^CD8^−^ double-negative (DN) T cells that produce IL-17 and IFN-*γ* expand in the peripheral blood of SLE patients, but not in healthy individuals \[[@B49]\]. In addition, DN T cells and IL-17-producing T cells are observed in the kidneys of patients with lupus nephritis. IL-17, IFN-*γ*, and IL-13 are the main cytokines produced by T cells that infiltrate in the kidneys of nephritic MRL/lpr mice \[[@B50]\]. IL-17-producing CD4^+^ T cells express IL-10R*α in vivo*, and T cell-specific blockade of IL-10 signaling leads to a selective increase in the numbers of IL-17 and IFN-*γ*-producing CD4^+^ T cells during intestinal inflammation \[[@B46]\]. Both CD4^+^Foxp3^−^ IL-10-producing cells and CD4^+^ Foxp3^+^ regulatory (Foxp3^+^ Treg) cells were found to control the numbers of Th17 cells and IL-17- and IFN-*γ*-producing cells in an IL-10-dependent manner *in vivo*. In addition, IL-10 treatment of mice with established colitis decreased the numbers of Th17 cells and IL-17 and IFN-*γ*-producing CD4^+^ T-cell frequencies through direct signaling in T cells. Consistent with our results, CD4^+^Foxp3^−^ IL-10-producing cells expressed LAG-3, in contrast to Foxp3^+^ Treg. Therefore, investigating the functions of CD4^+^CD25^−^LAG3^+^ Treg might lead to the development of novel treatments for SLE.

5. Role of TGF-***β*** in SLE {#sec5}
=============================

TGF-*β* functions to suppress inflammation and is important for the tolerance induced by oral antigen administration and for protecting against lymphopenia-induced colitis and thyroiditis mediated by the transfer of CD4^+^ T cells \[[@B51]\]. TGF-*β* can regulate autoaggressive T-cell responses by prevention of the APC maturation and can inhibit the differentiation of naïve CD4^+^ T cells into Th1 or Th2 effector cells by inhibiting T-bet, a Th1-specific transcription factor, and GATA-3, a transcription factor for Th2 differentiation \[[@B52]--[@B54]\]. In contrast to the development of naturally occurring CD4^+^CD25^+^ Treg \[[@B55]\], the peripheral induction of CD4^+^CD25^+^ Treg \[[@B56]\] depends on the effect of TGF-*β*. TGF-*β* signaling via TGF-*β* receptor is also required for the *de novo* expression of Foxp3 \[[@B57]\]. TGF-*β* signaling is required for the suppressive ability and the *in vivo* expansion of Tregs \[[@B58]\]. The TGF-*β*-induced transcription factor mother against decapentaplegic homologue 3 (SMAD3) have been shown to control the activity of a Foxp3 intronic enhancer element in cooperation with NFAT \[[@B59]\]. Recently, it has been shown that TGF-*β* increases the amount of acetylated Foxp3 protein bound to active chromatin sites, suggesting that TGF-*β* prolongs the half-life of Foxp3 RNA species and/or phosphorylates the chromatin-bound Foxp3, which might enable other transcription factors to undergo cellular compartment transitions for other transcription factors \[[@B60]\]. The suppressive effects of TGF-*β* can be transmitted to effector T cells through the soluble forms of this cytokine, or direct contact with Tregs, which display TGF-*β* on their surface \[[@B61]\]. When cell-to-cell contact takes place, TGF-*β* molecules on the surfaces of Tregs are triggered to aggregate by signals originating from CTLA-4 upon cell-to-cell contact \[[@B61]\]. T cells that cannot respond to TGF-*β*, thus, escape control by Tregs \[[@B62]\] to result in generalized autoimmunity *in vivo* \[[@B63]\].

Interestingly, the serum concentration of TGF-*β*1 is decreased in patients with active SLE, and urinary TGF-*β*1 levels are increased in patients with lupus nephritis \[[@B64], [@B65]\]. Patients with decreased numbers of CD4^+^CD25^+^ Treg tend to display lower serum TGF-*β*1 levels and higher urinary TGF-*β*1 levels. TGF-*β*1 might even play dual roles in murine lupus, immune regulation, and promotion of chronic end organ damage \[[@B66]\]. BWF~1~ mice have reduced expression of TGF-*β*1 in the spleen, and TGF-*β*1 or TGF-*β*1-producing T cells suppress autoantibody production. In contrast, the expression of TGF-*β*1 protein and TGF-*β*-signaling proteins increased in the kidneys. The levels of TGF-*β*1 in the kidneys and urine correlate with the extent of chronic lesions that represent local fibrosis. TGF-*β*1 blockade by treatment of these mice with an anti-TGF-*β* antibody *in vivo* selectively inhibits chronic fibrotic lesions without affecting autoantibody production and tissue inflammation. The use of TGF-*β*1 in association with CD4^+^CD25^+^ Treg might have potential as a novel therapeutic approach for autoimmune disease. However, we should be aware of chronic organ damage by TGF-*β*1.

6. Roles of IL-27 in SLE {#sec6}
========================

IL-27 is a member of the IL-12 family cytokines composed of Epstein-Barr virus-induced gene 3 (EBI-3) and p28 subunits \[[@B73], [@B74]\]. IL-27 is mainly produced by activated monocytes/macrophages and DCs but is also expressed by other cell types including the parenchymal cells \[[@B75]--[@B77]\]. The murine p28 subunit can be secreted by itself, but the human p28 subunit has to be bound to EBI-3 for secretion. Therefore, the expression of both the EBI-3 subunit and p28 subunit within the same cell appears to be necessary for IL-27 production in humans \[[@B78]\]. While the expression of each subunit is differentially regulated, toll-like receptor (TLR) signaling is an important trigger of the expression of the EBI-3 and p28 subunits \[[@B78]\]. It was reported that TLR4 mediates the upregulation of IL-27 expression via MyD88-dependent and independent mechanisms. In addition, NF-*κ*B signaling has also contributed to the induction of IL-27 expression \[[@B79], [@B80]\]. The administration of IL-27 suppressed the cytokine production of activated T cells *in vitro*\[[@B81]\]. IL-27 and its receptor, IL-27R, play an immunosuppressive role and suppress the production of proinflammatory cytokines. IL-27R consists of WSX-1 and gp130. WSX-1 is expressed in T cells, B cells, NK cells, monocytes, mast cells, dendritic cells (DCs), and endothelial cells \[[@B82]\]. Similar to other cytokine receptors, IL-27R signaling activates the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathways in a cell-type-dependent manner \[[@B83]--[@B85]\]. Collectively, these findings revealed a novel role for IL-27/WSX-1 as an attenuator of proinflammatory cytokine production, which is important for preventing excessive inflammation.

IL-27 is a pleiotropic cytokine that has both offensive and defensive properties. IL-27 is unique in that although it suppresses immune responses, it also plays a proinflammatory role by inducing Th1 differentiation \[[@B86]\]. The role of WSX-1 in Th1 differentiation has also been examined in *WSX-1^−/−^* mice. *WSX-1^−/−^* mice exhibited impaired IFN-*γ* production compared with wild-type mice \[[@B87], [@B88]\]. IL-27/WSX-1 signaling induces STAT1 or STAT3 activation, followed by the induction and activation of T-bet. Though naive CD4^+^ T cells do not produce IFN-*γ* in response to IL-27 stimulation, additional stimulation with IL-12 induces IFN-*γ* production by naive CD4^+^ T cells. IL-27/WSX-1 suppresses the expression of GATA-3 in a STAT1-dependent or independent manner, thereby, contributing to Th1 differentiation \[[@B89]\].

Experimental inflammatory responses were also enhanced in *WSX-1^−/−^* mice \[[@B90]\]. Recent studies have demonstrated that IL-27 promotes IL-10 production by CD4^+^ T cells \[[@B91], [@B92]\] and inhibits Th17 cells in mice and humans \[[@B93], [@B94]\]. These results suggest a dual regulatory mechanism of IL-27 for controlling autoimmunity and tissue inflammation. The IL-10-producing CD4^+^ T cells elicited by IL-27 are T-bet^+^FoxP3^−^IFN-*γ*^+^ \[[@B91], [@B92], [@B95]--[@B97]\], and STAT1 and STAT3 activities are involved in the induction of IL-10 by IL-27 \[[@B91]\]. The induction of c-Maf, IL-21, and ICOS expression seems to be required to IL-27-mediated, Tr1-like cell differentiation \[[@B98]\]. Whereas IL-10 induction is critical for IL-27-mediated immune suppression, IL-10-independent anti-inflammatory mechanisms have been indicated \[[@B91], [@B95]\]. For instance, IL-27 demonstrated suppressive effects in an IL-10-deficient milieu, and it even suppressed IL-10 production in some conditions \[[@B81]\]. In addition, IL-27 also suppresses inflammation by inhibiting Th17 cell differentiation *in vitro*\[[@B77]\]. IL-27 was reported to suppress the expression of the Th17-specific transcription factor ROR*γ*t \[[@B94]\].

Recently, the effects of IL-27 signaling on autoimmune responses in MRL/lpr mice were investigated. Deficiency of the WSX-1 gene resulted in the development of a disease resembling human membranous glomerulonephritis (WHO class V), and sera levels of IgG1 and IgE were increased. *WSX-1*^−*/*−^ MRL/lpr T cells exhibited significantly decreased IFN-*γ* production along with elevated IL-4 expression \[[@B99]\], and EBI-3 deficiency in MRL/lpr mice resulted in a disease resembling human membranous glomerulonephritis and sialadenitis \[[@B100]\]. On the other hand, transgenic overexpression of the WSX-1 gene in the T cells of MRL/lpr mice strongly suppressed the development of glomerulonephritis and improved survival, suggesting protective role of high-dose IL-27 in lupus \[[@B101]\]. Microarray analysis of glomerular gene expression in murine lupus nephritis revealed increased Ebi3 expression \[[@B102]\]. In addition, decreased serum IL-27 levels were observed in patients with SLE, especially those with nephritis. These findings suggest a protective role for IL-27 in SLE \[[@B103]\]. However, both the regulatory and proinflammatory functions of IL-27 should be investigated further, especially in humans. Recently, it was reported that the WSX-1 is required to support IL-21 production and follicular helper T-cell survival in a T-cell intrinsic manner \[[@B104]\]. Recombinant IL-27 molecules that have a long-lasting effect *in vivo*, small chemical compounds that promote IL-27/WSX-1 signaling, and antagonistic or agonistic anti-IL-27R antibodies would be useful as novel therapies for SLE.

7. Role of IL-35 in SLE {#sec7}
=======================

IL-35 is a newly identified inhibitory cytokine that belongs to the IL-12 cytokine family \[[@B67], [@B68]\]. It is composed of the IL-12*α* (p35) and EBI-3, which is considered to be a downstream target of Foxp3. IL-35 is preferentially expressed in CD4^+^CD25^+^ Treg, and ectopic expression of IL-35 confers regulatory activity on naïve T cells, whereas recombinant IL-35 suppresses T-cell proliferation \[[@B69]\]. IL-35 is required for maximal regulatory function *in vivo* as CD4^+^CD25^+^ Treg deficient in either subunit fail to control homeostatic T-cell expansion or inflammatory bowel disease \[[@B69]\]. Given that IL-35 was discovered relatively recently, our understanding of its biological activity is still limited. Compared with IL-12 and IL-27, generation and purification of recombinant IL-35 are challenging due to its instability. It is tempting to speculate that the apparent poor stability of IL-35 might underlie its important physiological roles and limit potency over short range. On the other hand, DC that secretes IL-12 or IL-27 might be precluded from generating IL-35, because of preferential pairing of IL-12 and IL-27.

IL-35 fusion protein was suggested to inhibit the differentiation of Th17 cells *in vitro* and to ameliorate collagen-induced arthritis (CIA) and suppress IL-17 secretion *in vivo* \[[@B70]\]. To precisely characterize the function of IL-35, the determination of the IL-35 receptor and its expression pattern is required. Its receptor will also be composed of a new combination of known family receptor chains \[[@B69]\], or the receptor might be composed of novel subunits. Lastly, it is unknown whether IL-35 can induce the formation of Tregs. This is a shared feature of the other two inhibitory cytokines IL-10 and TGF-*β*, and; thus, it remains plausible that IL-35 has a similar ability. Since TGF-*β*-induced Treg (Th3) and IL-10-induced Tr1 cells have very distinct transcriptional and functional profiles \[[@B71], [@B72]\], IL-35-induced regulatory populations may also exhibit quite distinct phenotype. The linkage between the regulatory role of IL-35 and lupus pathogenesis remains to be investigated.

8. Conclusions {#sec8}
==============

Accumulating data have revealed that the numbers and the function of CD4^+^CD25^+^ Treg are decreased in SLE. Other than CD4^+^CD25^+^ Treg, there are several Treg populations including IL-10-producing Tr1-like cells. Cooperation between these subsets of Tregs might be required for optimal immunoregulatory function ([Figure 1](#fig1){ref-type="fig"}). Investigations of Treg-associated cytokines, such as IL-10, TGF-*β*, IL-27, and IL-35, might aid the development of novel therapies for SLE. Indeed, the generation of T cells producing high levels of immunosuppressive cytokines in response to antigen specific stimulation successfully prevented autoimmune disease in animal models. Therapeutic approaches that induce functional Tregs with relevant antigen-specificities would restore immune homeostasis in patients and protect them from further autoimmune response. Further investigations in animal models and humans will hopefully allow lupus to be treated with Tregs and Treg-associated cytokines.

![The subsets of regulatory T cells. These Treg cells are candidates which prevent breakdown of self-tolerance and autoimmune diseases.](JBB2011-463412.001){#fig1}
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